Top 10 Evidence-Based Reasons to Get Genetic Testing (2026 Clinical Guidelines)

Genetic Tests: The truth people miss.

Mon, 23 Feb 2026 15:52:55 GMT

At a glance

You open your DNA report and it says “ high risk ” or “ low risk .” Most people do the same mistake: they treat it like a diagnosis.

But here’s the truth: a genetic test can be accurate… and still mislead you.

Here, we break down:

What consumer genetic tests can do
What they can’t do
The biggest mistake people make with “risk”
Genotyping vs full sequencing
Why you should care that DNA is permanent data.
The important questions to ask before you upload DNA anywhere
What to do with your results

Genes matter

They influence how your body builds proteins, processes signals, and responds to stressors, so they can shape your risk for certain traits and diseases.

But genes are not a crystal ball.

Most common health outcomes are shaped by a mix of:

genetics
lifestyle (sleep, diet, activity, stress)
environment (exposures, access to care, community factors)
family history and chance

So if you take one thing from this:
Genetics is not destiny. It’s one ingredient.

What genetic tests can do

Consumer DNA tests can be useful, if you know what they’re designed to report.

They can:

Tell you about ancestry and relatives (this is what they were originally built for).
Flag certain well-known variants, but only the ones they actually test for, and health-related findings may need clinical confirmation.
Estimate risk for complex traits influenced by many small genetic differences (often presented as a “risk score”).

Bottom line: These tests can provide clues, not final answers.

What genetic tests can't do

This is where the confusion happens.

Consumer genetic tests usually can’t:

Diagnose disease. Most illnesses aren’t “one gene = one outcome.”
See everything. Many consumer tests use genotyping , not full sequencing, meaning they sample specific markers instead of reading your entire DNA.
Replace a clinician or your context. A result’s meaning depends on your symptoms, family history, ancestry background, test coverage, and lifestyle.

Memorable rule: Risk ≠ diagnosis.

Genotyping vs sequencing (The easiest way to understand)

Think of your DNA like a book.

Genotyping is like browsing the book, checking a set of highlighted lines and “bookmarked” pages.
Full sequencing i s like reading the whole book, chapter by chapter, line by line.

Many consumer tests use genotyping. Genotyping can still be useful. But it’s important to remember:

If a test never looked for something, it can’t report it.

“Low risk” and “high risk” can both mislead you

A “low risk” result can create false reassurance.

Example: if your report says low risk for a condition, do you suddenly feel safe to ignore healthy habits?

A “high risk” result can do the opposite: it can drop anxiety into your life, even when:

there’s no clear action
the result isn’t clinically confirmed
the effect size is small
the test coverage is limited

So don’t just ask: “ Is my result true?”

Ask: “Is this result complete… and is it actionable? ”

Why you should care: DNA is permanent data

You can change your password. You can’t change your DNA. That’s why privacy and long-term control matter.

Reason 1: Long-term control

Taken from a case study when a major genetics company filed for Chapter 11 bankruptcy (March 2025 ) , it pushed uncomfortable questions into the spotlight:

What happens to customer genetic data when a company is under financial pressure?
Who controls genetic data over time?

2. Reason 2: Privacy

We’ve already seen how quickly a breach can expand.

In April 2023, investigators found attackers accessed 18,000+ customer accounts. But because some users opted into a DNA relatives feature, it didn’t stop there, connected sensitive info tied to nearly 7 million people was exposed.

Takeaway: Your account might be locked down, but connected features and opt-ins can widen what gets revealed.

Before you test with any company, ask:

Who can access my data, and what am I opting into?
How is it secured,and can I turn on extra protection like MFA?
How long is it stored, and can I delete it?
Will my data be shared for research, partners, or third parties, and is that opt-in or opt-out?

What to do with your results (the smart way)

Here’s how to use genetic tests responsibly:

1) Use consumer tests for curiosity and context, not medical decisions.
2) If you see something scary or truly actionable, confirm clinically and talk to a genetics-trained professional.
3) Protect your data: review sharing settings, opt out if you want, use strong passwords + MFA, and consider deleting your data if you’re uncomfortable.

F ULL REFERENCES

1) NHGRI / Genome.gov — Direct-to-Consumer Genetic Testing FAQ for Healthcare Professionals (2023)

https://www.genome.gov/For-Health-Professionals/Provider-Genomics-Education-Resources/Healthcare-Provider-Direct-to-Consumer-Genetic-Testing-FAQ

2) 23andMe Customer Care — Difference Between DNA Genotyping & Sequencing

https://customercare.23andme.com/hc/en-us/articles/202904600-Difference-Between-DNA-Genotyping-Sequencing

3) Gerke S, Jacoby MB, Cohen IG. Bankruptcy, Genetic Information, and Privacy—Selling Personal Information.

New England Journal of Medicine (2025). DOI: 10.1056/NEJMp2415835 https://pubmed.ncbi.nlm.nih.gov/40029207/

4) LoTempio JE Jr, Donohue CR, Moreno JD, Santos Rutschman A, Sarnoff J, Sinha MS, Stoeger T, Contreras JL.

Impact of the 23andMe bankruptcy on preserving the public benefit of scientific data. Nature Genetics (2025).

DOI: 10.1038/s41588-025-02423-8 https://pmc.ncbi.nlm.nih.gov/articles/PMC12695062/

5) Godoy J. FTC concerned about privacy protections in 23andMe bankruptcy. Reuters (March 31, 2025).

https://www.reuters.com/business/healthcare-pharmaceuticals/ftc-concerned-about-privacy-protections-23andme-bankruptcy-2025-03-31/

6) House Committee on Oversight and Government Reform — Comer Announces Hearing on 23andMe Bankruptcy to Safeguard Americans’ Private Genetic Data (June 5, 2025).

https://oversight.house.gov/release/comer-announces-hearing-on-23andme-bankruptcy-to-safeguard-americans-private-genetic-data/

7) Office of the Privacy Commissioner of Canada (OPC) — Backgrounder: Summary of joint investigation into data breach at 23andMe (June 17, 2025)

https://www.priv.gc.ca/en/opc-news/news-and-announcements/2025/bg_23andme_250617/

8) UK Information Commissioner’s Office (ICO) — Statement on 23andMe investigation (March 24, 2025)

https://ico.org.uk/about-the-ico/media-centre/news-and-blogs/2025/03/statement-on-23andme-investigation/

9) U.S. SEC — 23andMe Current Report (Form 8-K) (March 2025)

https://www.sec.gov/Archives/edgar/data/1804591/000119312525060817/d933650d8k.html

10) Kroll (claims agent) — 23andMe Restructuring (Chapter 11 case portal)

https://restructuring.ra.kroll.com/23andme/

Take a deep dive by watching the video below

Medicines That Heal but Can Harm: Pharmacogenetics (PGx)

Tue, 16 Dec 2025 12:46:00 GMT

At a glance

Ever wondered why a medicine can be a lifesaver for someone else but a disaster for you? Pharmacogenetics (PGx) explains why, and why it should be a priority.

Big problem: A noticeable chunk of hospital beds is filled by people harmed by their medicines.
Different genes, different reactions: The same dose can be too weak, just right, or dangerously strong depending on your genes.
Small panel, big reach: A few dozen key genes already influence how we respond to 100+ common medicines .
Future-proof info: One PGx test can guide many prescriptions across your lifetime, not just one drug today.

Medicine heals and hurts

Recent national and international studies suggest that around 2–6% of all hospital admissions are primarily caused by adverse drug reactions (ADRs); in older adults and those on many medicines, the proportion is even higher. ⁽¹⁾ ⁽²⁾

Among emergency readmissions, about 1 in 5 can be traced back to unwanted side effects, and many of these are considered potentially preventable . ⁽³⁾ ⁽⁴⁾

At the same time, 1.4 billion adults worldwide are living with hypertension (high blood pressure) , a major reason for taking long-term medication. Nearly half don’t know they have it, and only about 1 in 5 have their blood pressure under good control. ⁽⁵⁾ ⁽⁶⁾

So we have a double challenge:

Many people need complex medication plans.
A significant number get hurt by them or don’t respond as expected.

Pharmacogenetics is one of the tools that can help shift that balance.

What is pharmacogenetics, really?

Pharmacogenetics (PGx) looks at how your genes influence the way you process and respond to medicines :

Enzyme genes affect how quickly you break down a drug.
Transporter genes affect where the drug goes in the body.
Receptor and target genes affect how strongly it works.

The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes evidence-based guidelines designed to help clinicians understand HOW available genetic test results should be used to optimize drug therapy (rather than WHETHER tests should be ordered). ⁽⁷⁾

As summarized in recent CPIC publications, CPIC guidelines cover 34 genes and 164 drugs. turning genetic results into concrete prescribing advice. ⁽⁸⁾

In practice, a relatively small panel of genes can touch a large fraction of common prescriptions over a person’s life, because many widely used drug classes (pain, mental health, heart/clotting, cholesterol, oncology, immunology) have well-described gene–drug interactions. ⁽⁹⁾ ⁽¹⁰⁾

3. Concrete gene–drug examples (that people actually recognise)

Here are some everyday medicines people recognise where small genetic differences can change how well the drug works or how likely side effects are.

What pharmacogenetics can and can’t do

It can turn trial and error into smarter first guesses, especially for drugs where CPIC provides actionable dosing/selection guidance. ⁽⁷⁾ ⁽⁸⁾
It won’t magically pick the one perfect drug, because response also depends on diagnosis accuracy, dose, kidney/liver function, interactions, adherence, and time.
It does help reduce preventable harm for specific drug–gene pairs by flagging higher-risk situations (e.g., toxicity risk or non-response risk) before dose escalation. ⁽¹⁰⁾ ⁽⁹⁾
It doesn’t replace diagnosis, clinical monitoring, or listening to symptoms , it improves the decision-making around drug choice and dose when used in context.

How HealthCode.Gene fits in

At HealthCode.Gene, we fit into pharmacogenetics in two ways: we model, and we make it usable — always anchored to evidence-based guidance (CPIC/FDA) and the patient’s phenotype and medication context. ⁽⁷⁾ ⁽¹⁰⁾

Model: Build evidence-weighted models that integrate PGx signals with phenotype (age, kidney/liver function, comedications, dose history, symptoms) to support safer dose stratification and adverse reaction risk profiling.
Translate: Turn lab reports and model outputs into clear, plain-language “what this means / what to do next” explainers for patients, clinicians, and product teams.
Enable use: Create visuals/one-pagers and support research groups, clinics/medical spas, and startups in designing and communicating PGx-aware services and pilots, with guardrails that prevent over-interpretation.

References

Beeler PE, et al. Hospitalisations Related to Adverse Drug Reactions in Switzerland in 2012–2019: Characteristics, In-Hospital Mortality and Spontaneous Reporting Rate . Drugs . 2023. https://link.springer.com/article/10.1007/s40264-023-01319-y
Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients . BMJ . 2004;329(7456):15–19. doi:10.1136/bmj.329.7456.15. https://pubmed.ncbi.nlm.nih.gov/15231615/
Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Emergency re-admissions to hospital due to adverse drug reactions within 1 year of the index admission . British Journal of Clinical Pharmacology . 2010. https://pubmed.ncbi.nlm.nih.gov/21039769/
Banholzer S, Jäger J, Christen S, et al. Retrospective analysis of adverse drug reactions leading to short-term emergency hospital readmission . Swiss Medical Weekly . 2021. https://smw.ch/index.php/smw/article/view/2945
World Health Organization (WHO). Hypertension (Fact sheet). https://www.who.int/news-room/fact-sheets/detail/hypertension
World Health Organization (WHO). Uncontrolled high blood pressure puts over a billion people at risk . News release (23 Sep 2025). https://www.who.int/news/item/23-09-2025-uncontrolled-high-blood-pressure-puts-over-a-billion-people-at-risk
Clinical Pharmacogenetics Implementation Consortium (CPIC). CPIC Guidelines (evidence-based recommendations for how to use available PGx results). https://cpicpgx.org/guidelines/
Caudle KE, Whirl-Carrillo M, Relling MV, et al. Advancing Clinical Pharmacogenomics Worldwide Through the Clinical Pharmacogenetics Implementation Consortium (CPIC) . Clinical Pharmacology & Therapeutics . 2025;118(6):1512–1522. doi:10.1002/cpt.70005. https://pubmed.ncbi.nlm.nih.gov/40678821/
Clinical Pharmacogenetics Implementation Consortium (CPIC). Genes–Drugs . https://cpicpgx.org/genes-drugs/
U.S. Food and Drug Administration (FDA). Table of Pharmacogenomic Biomarkers in Drug Labeling . https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling

Back to section ↑

Why Genes Matter for your health

Thu, 04 Dec 2025 13:57:40 GMT

At a glance

Personalised health plans – care that fits your biology, not the average.
Risk detection & prevention – spot problems earlier, act sooner.
Smarter medicines – understand how drugs affect you and fine-tune doses.
Everyday habits that work – tailored nutrition, better choices, optimised fitness.

1 . Genes understanding help seeing problems earlier

Understanding your genetics can help you identify the problem earlier and get the solution sooner. For instance, some people inherit a higher chance of conditions such as heart disease, diabetes or certain cancers, and it is rarely about one single “bad gene”. Instead, modern genetics often combines thousands of tiny genetic signals into a polygenic risk scores (PRS) . a way of estimating inherited risk more realistically.

When PRS is added to the usual risk factors like age, blood pressure, cholesterol, smoking, and family history, it can sharpen risk prediction for things like cardiovascular disease, and help identify who might benefit most from earlier screening and preventive steps.

Big picture, genetics does not replace lifestyle or clinical care, it adds another useful layer, so prevention can be proactive, rather than waiting for disease to appear.

2 . Genes help with smart personalized prescription

The same prescription can work perfectly for one person, but cause side effects or do very little for another. One big reason is pharmacogenomics (PGx) , how your genes influence your response to medicines.

Some genetic variants affect drug-processing enzymes and drug targets in the body. This can change how quickly a medicine is broken down, how strongly it works, or whether you likely to experience a serious reaction.

When used upfront, PGx can help clinicians choose a better drug or dose from the start, reducing trial and error. Importantly, large prospective and real world studies of pre-emptive PGx testing show that using genetic information to guide drug and dose selection can reduce adverse drug reactions, hospital visits, and treatment failures, while improving safety and adherence.

PGx does not apply to every medication, but for many commonly used drugs, including some antidepressants, blood thinners, pain medicines, and certain cancer therapies, clinical guidelines already exist to support safer, more personalised prescribing.

3. Genes play a role in your lifestyle and everyday habits

Your genes influence how your body responds to food, exercise, sleep, and stress, but your habits still matter a lot. Here are two classic examples:

Weight & metabolism: One of the best-studied “weight-tendency” genes is FTO. The common risk variant is widespread, in people of European ancestry, roughly 40–50% carry at least one copy (and it varies a lot across populations). The important part is what happens next, large studies show that physical activity reduces the extra obesity risk linked to FTO by about 25–30% (around 27%). So even if you carry a higher-risk FTO version, movement still makes a meaningful difference.
Type 2 diabetes & metabolic health: Genetics can raise your baseline risk, but lifestyle can still push the trajectory in a better direction. A systematic review of gene–lifestyle interactions supports the idea that habits like diet and physical activity can modify inherited risk for type 2 diabetes.

The big picture: genes set the stage and lifestyle shapes a lot of the outcome. That’s why one size fits all advice, like “10,000 steps” or “the same diet for everyone,” can miss what matters most for you. Genetic insights can help you prioritise the habits with the biggest payoff, from nutrition and movement to sleep and stress, and we go deeper with practical, research-backed explainers in our HealthCode.Gene resources.

4. What genetics can and can’t do

Genetics can help you understand risk, but it can’t predict your future on its own.

Most common diseases aren’t caused by one gene. They come from a mix of genes + lifestyle + environment (and sometimes chance).
A “high risk” genetic result means your chance is higher, it does not mean you will definitely get the disease.
A “low risk” result means your chance is lower, it does not mean you’re protected. Habits like smoking, inactivity, poor diet, and long-term stress can still raise risk.
Genetics should support not replace medical care, prevention, and good daily habits.
Used well, genetics helps you have better conversations: clearer risk, realistic expectations, and more personalised choices.

5. How HealthCode Gene uses this science

Genetic & Health Literacy Content
We turn complex genetics into clear stories – reels, carousels, one-pagers and blog posts that explain how genes, medicines and lifestyle interact.
Omics, Modelling & Precision Health Analytics
We support researchers, clinicians and companies with custom bioinformatic analyses, omics pipelines and predictive models, plus publication-ready figures and methods.
Your Genes, Your Meds (PGx)
We convert dense pharmacogenetic lab reports into plain-language medication summaries that link your genes to drug choice, dose and side-effects.
Workshops & Talks
We run interactive sessions with health and genetics experts to help teams, clinics and partners understand and apply genetics in practice.
Technology & Product Explainability
We help make gene tests, digital tools and MedTech products, Research papers understandable for patients, partners and investors through simple wording, visuals and decks.

Where your genes meet your everyday habits, decisions can become earlier, safer and more personalised .

References for the science curious

Polygenic Risk Scores in Cardiovascular Diseases

O’Sullivan JW et al. Polygenic risk scores for cardiovascular disease: contemporary science and clinical considerations. Circulation. 2022. https://pubmed.ncbi.nlm.nih.gov/35862132/
Gupta A et al. A review on polygenic risk scores in cardiovascular diseases. Advances in Biomarker Sciences and Technology. 2025. https://www.sciencedirect.com/science/article/pii/S2543106425000225
Ntritsos G et al. Impact of polygenic risk score for coronary artery disease on physician decision-making and patient care. Front Genet. 2025. https://pubmed.ncbi.nlm.nih.gov/40786866/

Pharmacogenomics testing & Adverse Reactions

Chenchula S et al. A review of real-world evidence on pre-emptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care. Pharmacogenomics J. 2024. https://pubmed.ncbi.nlm.nih.gov/38490995/
Skokou M et al. Clinical implementation of preemptive pharmacogenomics in psychiatry. EBioMedicine. 2024. https://pubmed.ncbi.nlm.nih.gov/38364700/

Lifestyle–gene interactions

Kilpeläinen TO et al. Physical activity attenuates the influence of FTO variants on obesity risk: meta-analysis of 218,166 adults and 19,268 children. PLoS Med. 2011.
https://pubmed.ncbi.nlm.nih.gov/22069379/
Dietrich S et al. Gene–lifestyle interaction on risk of type 2 diabetes: a systematic review. Obes Rev. 2019.
https://pubmed.ncbi.nlm.nih.gov/31478326/
Temelkova-Kurktschiev T & Stefanov T. Lifestyle and genetics in obesity and type 2 diabetes. Exp Clin Endocrinol Diabetes. 2012;120(1):1–6. https://pubmed.ncbi.nlm.nih.gov/21915815/